PT1070056E - Inibidores de pde iii/iv a base de ftalazinona - Google Patents

Inibidores de pde iii/iv a base de ftalazinona

Info

Publication number
PT1070056E
PT1070056E PT99914474T PT99914474T PT1070056E PT 1070056 E PT1070056 E PT 1070056E PT 99914474 T PT99914474 T PT 99914474T PT 99914474 T PT99914474 T PT 99914474T PT 1070056 E PT1070056 E PT 1070056E
Authority
PT
Portugal
Prior art keywords
ftalazinone
inhibitors based
pde iii
pde
iii
Prior art date
Application number
PT99914474T
Other languages
English (en)
Portuguese (pt)
Inventor
Rolf Beume
Dietrich Hafner
Hans-Peter Kley
Hildegard Boss
Armin Hatzelmann
Margaretha Van Der Mey
Ivonne Johanna Van Der Laan
Hendrik Timmerman
Geert Jan Sterk
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of PT1070056E publication Critical patent/PT1070056E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT99914474T 1998-03-14 1999-03-04 Inibidores de pde iii/iv a base de ftalazinona PT1070056E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98104643 1998-03-14
PCT/EP1999/001413 WO1999047505A1 (en) 1998-03-14 1999-03-04 Phthalazinone pde iii/iv inhibitors

Publications (1)

Publication Number Publication Date
PT1070056E true PT1070056E (pt) 2004-11-30

Family

ID=8231589

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99914474T PT1070056E (pt) 1998-03-14 1999-03-04 Inibidores de pde iii/iv a base de ftalazinona

Country Status (12)

Country Link
US (1) US6255303B1 (https=)
EP (1) EP1070056B1 (https=)
JP (1) JP2002506856A (https=)
AT (1) ATE270278T1 (https=)
AU (1) AU3328499A (https=)
CA (1) CA2323771A1 (https=)
DE (1) DE69918422T2 (https=)
DK (1) DK1070056T3 (https=)
ES (1) ES2224628T3 (https=)
PT (1) PT1070056E (https=)
SI (1) SI1070056T1 (https=)
WO (1) WO1999047505A1 (https=)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
AU7654200A (en) * 1999-09-14 2001-04-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone derivatives as pd3/4 inhibitors
HUP0203487A2 (hu) 1999-10-25 2003-02-28 Byk Gulden Lomberg Chemische Fabrik Gmbh Tetrahidrotiopirán-ftalazinon-származékok, mint PDE4-inhibitorok és ezeket tartalmazó gyógyszerkészítmények
WO2001030766A1 (en) 1999-10-25 2001-05-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone derivatives as pde 4 inhibitors
SI1775305T1 (sl) 2000-08-05 2015-01-30 Glaxo Group Limited S-fluorometil ester 6alfa,9alfa-difluoro-17alfa-((2-furanilkarboksil)oksi)- 11beta-hidroksi-16alfa-metil-3-okso-androst-1,4-dien-17-karbotiojske kisline kot protivnetno sredstvo
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
CZ20032491A3 (cs) 2001-02-15 2004-01-14 Altana Pharma Ag Ftalazinonpiperidinové deriváty
ES2296923T3 (es) 2001-03-22 2008-05-01 Glaxo Group Limited Derivados formanilidas como agonistas del adrenorreceptor beta2.
EP1385848A2 (en) * 2001-04-25 2004-02-04 ALTANA Pharma AG Phtalazinones derivatives useful as pde4/7 inhibitors
BR0209076A (pt) * 2001-04-25 2004-08-10 Altana Pharma Ag Derivados de piperazino e seu uso como inibidor de pde4
KR100831534B1 (ko) 2001-04-30 2008-05-22 글락소 그룹 리미티드 17.알파 위치에 시클릭 에스테르기를 지닌 항염증성의안드로스탄의 17.베타.-카르보티오에이트 에스테르 유도체
WO2003008396A1 (en) * 2001-07-16 2003-01-30 Nikken Chemicals Co., Ltd. Optically active oxazine derivative
US20030073711A1 (en) * 2001-08-23 2003-04-17 Whitehead Clark M. Methods for treatment of scleroderma
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
KR20090057477A (ko) 2001-09-14 2009-06-05 글락소 그룹 리미티드 호흡기 질환 치료용 펜에탄올아민 유도체
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
JP2005523920A (ja) 2002-04-25 2005-08-11 グラクソ　グループ　リミテッド フェネタノールアミン誘導体
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
BR0313330A (pt) * 2002-08-10 2005-06-14 Altana Pharma Ag Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4
WO2004018449A1 (en) * 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
EP1556369A1 (en) * 2002-08-10 2005-07-27 ALTANA Pharma AG Pyridazinone-derivatives as pde4 inhibitors
US20060166995A1 (en) * 2002-08-10 2006-07-27 Altana Pharma Ag Piperidine-n-oxide-derivatives
EP1556342B1 (en) 2002-10-28 2008-03-26 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
GB0329182D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
DE602005005638T2 (de) * 2004-02-04 2009-05-14 Nycomed Gmbh 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-on-derivate als pde4-inhibitoren
US20080227790A1 (en) * 2004-02-04 2008-09-18 Altana Pharma Ag Pyridazinone Derivatives and their Use as Pde4 Inhibitors
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
EP1841780B1 (en) 2005-01-10 2011-07-27 Glaxo Group Limited Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
MY145343A (en) 2005-03-25 2012-01-31 Glaxo Group Ltd Novel compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
PE20071068A1 (es) 2005-12-20 2007-12-13 Glaxo Group Ltd Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
MX2008013411A (es) 2006-04-20 2008-11-04 Glaxo Group Ltd Nuevos compuestos.
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
HRP20130044T1 (hr) 2006-07-25 2013-02-28 Cephalon, Inc. Derivati piridizinona
JPWO2008111631A1 (ja) * 2007-03-14 2010-06-24 日本新薬株式会社 α−メチルベンジルアミン塩の製法
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
MX2010012814A (es) 2008-05-23 2010-12-20 Amira Pharmaceuticals Inc Inhibidor de proteina activadora de 5-lipoxigenasa.
US8163743B2 (en) 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
PH12012502374A1 (en) 2008-06-24 2014-11-12 Hoffmann La Roche Novel substituted pyridin-2-ones and pyridazin-3-ones
PE20110164A1 (es) * 2008-07-02 2011-03-28 Hoffmann La Roche Nuevas fenilpirazinonas como inhibidores de quinasa
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
EP2408769A1 (en) 2009-03-17 2012-01-25 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
EP2408916A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2408458A1 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012520684A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢＴＢａｎｄＣＮＣＨｏｍｏｌｏｇｙ１（塩基性ロイシンジッパー転写因子１）（Ｂａｃｈ１）遺伝子発現のＲＮＡ干渉媒介性阻害
US20120029054A1 (en) 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
WO2010111471A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111497A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2411018A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
EP2411520A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521760A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2421834A1 (en) 2009-04-24 2012-02-29 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
AR076373A1 (es) 2009-04-24 2011-06-08 Glaxo Group Ltd N-pirazolil carboxamidas como inhibidores de canales de calcio
LT2899191T (lt) 2009-04-30 2017-10-25 Glaxo Group Limited Oksazolo pakeistieji indazolai kaip pi3-kinazės inhibitoriai
KR101742252B1 (ko) 2009-07-15 2017-05-31 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 비페닐 화합물의 결정질 유리 염기형
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
JP2013512880A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
EP3020393B1 (en) 2009-12-16 2020-10-07 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
RS54286B1 (sr) 2010-09-08 2016-02-29 Glaxosmithkline Intellectual Property Development Limited Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2(metiloksi)-3-piridinil]-metansulfonamida
US9326987B2 (en) 2010-09-08 2016-05-03 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
EP2630127A1 (en) 2010-10-21 2013-08-28 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
US9156791B2 (en) 2010-10-21 2015-10-13 Glaxo Group Limited Pyrazole compounds acting against allergic, immune and inflammatory conditions
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
EP2683716A1 (en) 2011-03-11 2014-01-15 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
US20140112945A1 (en) * 2011-06-17 2014-04-24 Takeda Gmbh Novel phthalazinone-pyrrolopyrimidinecarboxamide derivatives
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
EP2968323A4 (en) 2013-03-13 2016-12-14 Flatley Discovery Lab PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
WO2014159776A1 (en) * 2013-03-14 2014-10-02 Cephalon, Inc. Solid state forms of 6-[4-[3-(r)-2-methylpyrrolidine-1-yl)-propoxy]phenyl]2h-pyridazine-3-one hydrochloride
RU2016112268A (ru) 2013-10-17 2017-11-22 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Ингибитор PI3K для лечения респираторного заболевания
WO2015055691A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
US20170100385A1 (en) 2014-05-12 2017-04-13 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions comprising danirixin for treating infectious diseases
BR112017002970B1 (pt) 2014-08-14 2023-04-11 F. Hoffmann-La Roche Ag Novas piridazonas e triazinonas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
CN104478809B (zh) * 2014-11-14 2016-08-17 成都新恒创药业有限公司 一种左西孟旦杂质及其制备和检测方法
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
US20190161480A1 (en) 2016-08-08 2019-05-30 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
WO2018094392A1 (en) 2016-11-21 2018-05-24 Lupin Inc. Medicament dispenser
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
US20210085897A1 (en) 2018-04-06 2021-03-25 Lupin Inc. Medicament dispenser
WO2020058823A1 (en) 2018-09-17 2020-03-26 Lupin, Inc. Dose indicator assembly for a medicament dispenser
WO2021195353A1 (en) 2020-03-25 2021-09-30 Lupin Inc. Multi-carrier medicament dispensers
EP4185997A1 (en) 2020-07-23 2023-05-31 Lupin Inc. Dose counter assemblies for medicament dispensers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58116471A (ja) * 1981-12-29 1983-07-11 Nippon Kayaku Co Ltd ４−ヒドロキシメチル−１−フタラゾンエステル誘導体およびその塩
NZ257955A (en) * 1992-12-02 1996-05-28 Pfizer Catechol diethers pharmaceutical compositions
EP0634404A1 (en) * 1993-07-13 1995-01-18 Rhone Poulenc Agriculture Ltd. Phtalazin derivatives and their use as pesticides
DE19533975A1 (de) * 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
BR9806752A (pt) * 1997-01-15 2000-03-14 Byk Gulden Lomberg Chem Fab Ftalazinonas.

Also Published As

Publication number Publication date
US6255303B1 (en) 2001-07-03
CA2323771A1 (en) 1999-09-23
JP2002506856A (ja) 2002-03-05
EP1070056B1 (en) 2004-06-30
EP1070056A1 (en) 2001-01-24
ATE270278T1 (de) 2004-07-15
DE69918422D1 (de) 2004-08-05
ES2224628T3 (es) 2005-03-01
DE69918422T2 (de) 2005-08-11
WO1999047505A1 (en) 1999-09-23
SI1070056T1 (en) 2004-12-31
DK1070056T3 (da) 2004-11-08
AU3328499A (en) 1999-10-11

Similar Documents

Publication Publication Date Title
PT1070056E (pt) Inibidores de pde iii/iv a base de ftalazinona
MX9700557A (es) Dihidrobenzofuranos.
AU5414000A (en) Compounds
YU83302A (sh) Jedinjenja pirolo (2,3-d) pirimidina kao imunosupresivni agensi
BR0213140A (pt) Fungicidas de pirazol-pirimidina
EA200301100A1 (ru) Новые фталазиноны
YU19499A (sh) Benzonaftiridini kao bronhijalni terapeutici
DE69821530D1 (de) Dihydrobenzifurane
PT1086096E (pt) Benzamidas com substituintes etra-hidrofuraniloxi como inibidores da fosfodiesterase 4
EA200600607A1 (ru) Производные имидазопиридина в качестве ингибиторов индуцируемой no-синтазы
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
ATE287403T1 (de) 6-phenylbenzonaphthyidine
MXPA03003942A (es) Compuestos bis-heterociclicos con actividad antitumoral y quimiosensibilizante.
ATE320422T1 (de) Metalloproteinase inhibitoren
DE60036558D1 (de) Phthalazinon-derivate als pde 4 hemmer
AP2001002045A0 (en) FKBP inhibitors.
ATE269313T1 (de) Tryptase-inhibitoren
EA200600608A1 (ru) Производные имидазопиридина как ингибиторы индуцируемой no-синтазы
ATE268322T1 (de) Inhibitoren der tryptase
ATE360021T1 (de) Neue benzonaphthyridine
SI0937075T1 (en) New Imidazo- and Oxazolopyridines as Phosphodiesterase Inhibitors.
HRP20050293A2 (en) Novel benzonaphthyridines
AP2001002047A0 (en) Isoquinoliness as urokinase inhibitors.